3Colwell JA. Is it time to introduce metformine in the U. S. ? Diabetes Care , 1993,16 : 653-655.
4Anonymous. UKPDS Group : Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes.Lancet, 1998,352 : 837-853.
5Gentile S, Turco S, Guarino G, et al. Aminotransferase activity and acarbose treatment in patients with type 2 diabetes. Diabetes Care ,1999,22:1217-1218.
6Haupt E, Knick B, Koschinsky T, et al. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabetes Metab ,1991,17:224-231.
7Holman RR , Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years. Diabetes Care, 1999,22 : 960-964.
3Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development of longterm complications in insulin-dependent diabetes mellitus [J]. N Engl J Med, 1993,329:977-986.
4UK Prospective Diabetes Study (UDPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS) [J]. Lancet,1998,352:837-853.
5American Diabetes Association. Clinical practice recommendations [J]. Diabcctcs Care,2003,26(Suppl1):S33-S50.
6Lee WC, Conner C, Hammer M. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin,glimepiride,or both for the treatment of type 2 diabetes in the United States. ClinTher,2010,32 (10) : 1756.
7St Charles M, Minshall ME, Pandya B J, et al. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus mefformin from a third-party payer perspective in the US. Curr Med Res Opin,2009,25 (6) : 1343.
8Palmer JL, Beaudet A, White J, et al. Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China. Adv Ther,2010,27 (11) :814.
